Pediatric Blood & Cancer · 2011 · 33 citations · 10 references
MedicineImmunologyOncologyChemotherapyImmunotherapyStem Cell TransplantationCancer ImmunotherapyCancer Stem CellsCell-based ImmunotherapyCombination ImmunotherapyTransplant ImmunotherapyImmunotherapy After TransplantationPost-transplant Relapse ProphylaxisRefractory Neuroblastoma
Little is known on strategies to prevent or to treat relapses occurring after haploidentical stem cell transplantation (haplo-HSCT) performed for the high-risk neuroblastoma (NB). We describe a 6-year-old male with refractory NB who relapsed 22 months after haplo-HSCT. A complete remission was obtained with a combination of immuno-chemotherapy based on donor NK cells transplants, IL2 infusions and temozolomide/topotecan. This case is an incentive to explore both the immediate therapeutic effect of haplo-graft provided via haplo-NK cells and the immunogenic platform that haplo-HSCT offers for future treatment. Our post-relapse strategy shows that chemo- and bio-treatment should be viewed as complementary therapeutic options.
10
Katherine K. Matthay, C. Patrick Reynolds, Robert C. Seeger et al. · Journal of Clinical Oncology · 2009 · 856 citations
Medicine, Oncology, Chemotherapy +6